Editas Medicine (EDIT) Competitors $1.21 -0.04 (-3.20%) (As of 12/24/2024 05:19 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends EDIT vs. SANA, CYRX, ALMS, IGMS, TSHA, CTNM, GHRS, RGNX, YMAB, and DSGNShould you be buying Editas Medicine stock or one of its competitors? The main competitors of Editas Medicine include Sana Biotechnology (SANA), Cryoport (CYRX), Alumis (ALMS), IGM Biosciences (IGMS), Taysha Gene Therapies (TSHA), Contineum Therapeutics (CTNM), GH Research (GHRS), REGENXBIO (RGNX), Y-mAbs Therapeutics (YMAB), and Design Therapeutics (DSGN). These companies are all part of the "pharmaceutical products" industry. Editas Medicine vs. Sana Biotechnology Cryoport Alumis IGM Biosciences Taysha Gene Therapies Contineum Therapeutics GH Research REGENXBIO Y-mAbs Therapeutics Design Therapeutics Editas Medicine (NASDAQ:EDIT) and Sana Biotechnology (NASDAQ:SANA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings, community ranking and institutional ownership. Which has more volatility and risk, EDIT or SANA? Editas Medicine has a beta of 1.87, indicating that its share price is 87% more volatile than the S&P 500. Comparatively, Sana Biotechnology has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Does the media refer more to EDIT or SANA? In the previous week, Editas Medicine had 3 more articles in the media than Sana Biotechnology. MarketBeat recorded 3 mentions for Editas Medicine and 0 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 0.00 beat Editas Medicine's score of -0.28 indicating that Sana Biotechnology is being referred to more favorably in the news media. Company Overall Sentiment Editas Medicine Neutral Sana Biotechnology Neutral Is EDIT or SANA more profitable? Sana Biotechnology has a net margin of 0.00% compared to Editas Medicine's net margin of -340.96%. Editas Medicine's return on equity of -80.13% beat Sana Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets Editas Medicine-340.96% -80.13% -50.99% Sana Biotechnology N/A -84.22%-44.97% Do analysts prefer EDIT or SANA? Editas Medicine currently has a consensus target price of $7.00, suggesting a potential upside of 478.51%. Sana Biotechnology has a consensus target price of $13.50, suggesting a potential upside of 671.43%. Given Sana Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Sana Biotechnology is more favorable than Editas Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Editas Medicine 2 Sell rating(s) 9 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.07Sana Biotechnology 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Do institutionals and insiders believe in EDIT or SANA? 71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are owned by institutional investors. 1.9% of Editas Medicine shares are owned by insiders. Comparatively, 31.1% of Sana Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in EDIT or SANA? Editas Medicine received 295 more outperform votes than Sana Biotechnology when rated by MarketBeat users. However, 58.06% of users gave Sana Biotechnology an outperform vote while only 53.23% of users gave Editas Medicine an outperform vote. CompanyUnderperformOutperformEditas MedicineOutperform Votes31353.23% Underperform Votes27546.77% Sana BiotechnologyOutperform Votes1858.06% Underperform Votes1341.94% Which has stronger valuation and earnings, EDIT or SANA? Editas Medicine has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEditas Medicine$61.76M1.62-$153.22M-$2.56-0.47Sana BiotechnologyN/AN/A-$283.26M-$1.40-1.25 SummarySana Biotechnology beats Editas Medicine on 9 of the 16 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDIT vs. The Competition Export to ExcelMetricEditas MedicineBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$99.88M$2.96B$5.22B$9.27BDividend YieldN/A1.91%5.12%4.30%P/E Ratio-0.4745.6887.3417.27Price / Sales1.62417.621,166.41119.73Price / CashN/A174.7643.2337.83Price / Book0.283.924.834.93Net Income-$153.22M-$42.00M$120.46M$225.34M7 Day Performance-10.04%3.88%2.84%4.14%1 Month Performance-49.16%-0.22%19.70%1.16%1 Year Performance-88.83%18.86%30.57%16.98% Editas Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDITEditas Medicine4.4385 of 5 stars$1.21-3.2%$7.00+478.5%-88.8%$99.88M$61.76M-0.47230SANASana Biotechnology2.1289 of 5 stars$1.76+7.7%$13.50+669.2%-60.0%$391.84MN/A-1.25328CYRXCryoport2.8533 of 5 stars$7.87+2.3%$12.29+56.1%-51.1%$389.02M$226.11M-2.331,170ALMSAlumisN/A$8.06-3.7%$26.83+232.9%N/A$380.61MN/A0.00N/ALockup ExpirationIGMSIGM Biosciences4.5831 of 5 stars$6.40-1.7%$17.75+177.3%-23.4%$380.57M$2.92M-1.76190TSHATaysha Gene Therapies3.9165 of 5 stars$1.85+1.1%$6.63+258.1%+13.5%$379.15M$9.92M2.94180Positive NewsCTNMContineum Therapeutics2.2584 of 5 stars$14.41+1.9%$29.25+103.0%N/A$371.46M$50M0.0031GHRSGH Research1.4877 of 5 stars$7.09+1.3%$35.67+403.1%+29.1%$368.88MN/A-8.9710RGNXREGENXBIO4.6163 of 5 stars$7.40+0.3%$35.27+376.7%-60.3%$366.63M$84.33M-1.47344YMABY-mAbs Therapeutics2.3853 of 5 stars$8.14+0.4%$20.89+156.6%+20.0%$364.58M$84.55M-15.07150DSGNDesign Therapeutics0.9348 of 5 stars$6.35+2.3%$7.00+10.2%+137.8%$359.54MN/A-7.4740 Related Companies and Tools Related Companies Sana Biotechnology Competitors Cryoport Competitors Alumis Competitors IGM Biosciences Competitors Taysha Gene Therapies Competitors Contineum Therapeutics Competitors GH Research Competitors REGENXBIO Competitors Y-mAbs Therapeutics Competitors Design Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EDIT) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
